Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £21 | £34 | £22 | £34 |
| % Growth | -38.2% | 57.3% | -35.6% | – |
| Cost of Goods Sold | £17 | £13 | £12 | £13 |
| Gross Profit | £4 | £21 | £9 | £21 |
| % Margin | 20.3% | 61.3% | 42.6% | 61.1% |
| R&D Expenses | £8 | £8 | £12 | £11 |
| G&A Expenses | £14 | £5 | £12 | £11 |
| SG&A Expenses | £21 | £20 | £21 | £21 |
| Sales & Mktg Exp. | £15 | £5 | £9 | £10 |
| Other Operating Expenses | -£2 | £0 | £0 | -£0 |
| Operating Expenses | £27 | £28 | £33 | £32 |
| Operating Income | -£23 | -£7 | -£23 | -£12 |
| % Margin | -107.5% | -20% | -107.8% | -35.4% |
| Other Income/Exp. Net | -£6 | -£5 | -£1 | -£3 |
| Pre-Tax Income | -£29 | -£11 | -£24 | -£15 |
| Tax Expense | -£0 | -£0 | £0 | £1 |
| Net Income | -£29 | -£11 | -£25 | -£16 |
| % Margin | -138.2% | -32.6% | -113.6% | -46.6% |
| EPS | -0.006 | -0.002 | -0.007 | -0.006 |
| % Growth | -165.2% | 64.6% | -12.1% | – |
| EPS Diluted | -0.006 | -0.002 | -0.007 | -0.006 |
| Weighted Avg Shares Out | 4,766 | 4,766 | 3,759 | 2,699 |
| Weighted Avg Shares Out Dil | 4,766 | 4,766 | 3,759 | 2,720 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £4 | £3 | £1 | £3 |
| Depreciation & Amortization | £2 | £2 | £2 | £2 |
| EBITDA | -£23 | -£6 | -£21 | -£10 |
| % Margin | -109.3% | -19% | -97.3% | -28.9% |